No products in the cart.
Rabbit Polyclonal Phospho-Akt2 (S474) antibody (STJ90169)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC, ELISA
Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:20000;
Recommended protocols: check protocols
Click or hover above images to see image description for Akt2 (phospho Ser474) Polyclonal Antibody.
Check alternative names for the antibodyExpand
AKT2 antibody,|Akt2 antibody|AKT2_HUMAN antibody|HIHGHH antibody|murine thymoma viral (v-akt) homolog-2 antibody|PKB antibody|PKB beta antibody|PKBB antibody|PKBBETA antibody|PRKBB antibody|Protein kinase Akt 2 antibody|Protein kinase Akt-2 antibody|Protein kinase B beta antibody|rac protein kinase beta antibody|RAC-BETA antibody|RAC-beta serine/threonine-protein kinase antibody|RAC-PK-beta antibody|v akt murine thymoma viral oncogene homolog 2 antibody|Phospho anti-AKT2 (S474) antibody (ab38513)
SCBT cat No: sc-81148|sc-81436|sc-7127|sc-5270|sc-11520|
Akt2 (phospho Ser474) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
Phospho-Akt2 (S474) Polyclonal Antibody detects endogenous levels of Akt2 protein only when phosphorylated at S474.
Synthesized phospho-peptide derived from Akt2 (phospho Ser474) at AA range 400-480
WB, IHC, ELISA
|Recommended dilution|| |
WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:20000;
|Molecular weight|| |
Akt2 (phospho Ser474) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Akt2 (phospho Ser474) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
RAC-beta serine/threonine-protein kinase antibody, Protein kinase Akt-2 antibody, Protein kinase B beta antibody, PKB beta antibody, RAC-PK-beta antibody
|Protein names|| |
RAC-beta serine/threonine-protein kinase , Protein kinase Akt-2 , Protein kinase B beta , PKB beta , RAC-PK-beta
|Protein function|| |
AKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at ‘Ser-50’ negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at ‘Ser-21’ and GSK3B at ‘Ser-9’, resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of ‘Ser-83’ decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at ‘Ser-939’ and ‘Thr-1462’, thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at ‘Thr-24’, ‘Ser-256’ and ‘Ser-319’. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates ‘Ser-454’ on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of ‘Ser-273’, resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on ‘Ser-318’, which results in increased PI3P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI3K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. / One of the few specific substrates of AKT2 identified recently is PITX2. Phosphorylation of PITX2 impairs its association with the CCND1 mRNA-stabilizing complex thus shortening the half-life of CCND1. AKT2 seems also to be the principal isoform responsible of the regulation of glucose uptake. Phosphorylates C2CD5 on ‘Ser-197’ during insulin-stimulated adipocytes. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis. Phosphorylates CLK2 on ‘Thr-343’. / ATP + a protein = ADP + a phosphoprotein. / Two specific sites, one in the kinase domain (Thr-309) and the other in the C-terminal regulatory region (Ser-474), need to be phosphorylated for its full activation. Aminofurazans are potent AKT2 inhibitors. / 358.4 µM for ATP (for purified and in vitro activated AKT2) / 3.4 µM for peptide substrate (for purified and in vitro activated AKT2) / 564 µM for ATP (for recombinant myristoylated AKT2 expressed and immunoprecipitated from Rat-1 cells) / 2.3 µM for peptide substrate (for recombinant myristoylated AKT2 expressed and immunoprecipitated from Rat-1 cells)
|Protein tissue specificity|| |
Expressed in all cell types so far analyzed.
|Involvement in disease|| |
Note: Defects in AKT2 are a cause of susceptibility to breast cancer (BC). AKT2 promotes metastasis of tumor cells without affecting the latency of tumor development. With AKT3, plays also a pivotal role in the biology of glioblastoma.; Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body’s own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Hypoinsulinemic hypoglycemia with hemihypertrophy (HIHGHH) [MIM:240900]: A disorder characterized by hypoglycemia, low insulin levels, low serum levels of ketone bodies and branched-chain amino acids, left-sided hemihypertrophy, neonatal macrosomia, reduced consciousness and hypoglycemic seizures. . Note: The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Binding of the PH domain to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase alpha (PIK3CA) activity results in its targeting to the plasma membrane. / Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily. / Contains 1 AGC-kinase C-terminal domain. / Contains 1 PH domain. / Contains 1 protein kinase domain.
|Protein post-translational modifications|| |
Phosphorylation on Thr-309 and Ser-474 is required for full activity. / Ubiquitinated; undergoes both ‘Lys-48’- and ‘Lys-63’-linked polyubiquitination. TRAF6-induced ‘Lys-63’-linked AKT2 ubiquitination. When fully phosphorylated and translocated into the nucleus, undergoes ‘Lys-48’-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome. / O-GlcNAcylation at Thr-306 and Thr-313 inhibits activating phosphorylation at Thr-309 via disrupting the interaction between AKT and PDK1.
|Protein cellular localization|| |
Cytoplasm / Nucleus / Cell membrane; Peripheral membrane protein / Early endosome
AntibodyPlus can customize Akt2 (phospho Ser474) Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: